ADC Therapeutics: Updated data from Phase 2 Zynlonta study published in Lancet

ADC Therapeutics (ADCT) announced updated data from the investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA in combination with rituximab to treat relapsed or refractory follicular lymphoma were published in the December issue of The Lancet Haematology, following an oral presentation of the data at the recent 66th American Society of Hematology Annual Meeting and Exposition. “We are excited by the publication of these results in The Lancet Haematology demonstrating ZYNLONTA’s robust clinical activity in follicular lymphoma, particularly in patients classified as high-risk POD24 and those with high tumor burden where there remains significant unmet need,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. “In addition, encouraging data from another investigator-initiated trial of ZYNLONTA as a single agent to treat marginal zone lymphoma were also presented at ASH. Collectively, we believe these data underscore ZYNLONTA’s promise for patients with indolent B-cell lymphomas and add to a growing body of evidence showing the potential of ZYNLONTA beyond diffuse large B-cell lymphoma.”